braf

A discussion of a phase 2 trial of a MEK inhibitor in patients with V600 BRAF mutations and consideration of other relevant results with targeted therapies in this population.

This podcast will discuss the current role of characterizing KRAS and BRAF in the management of colorectal cancer as well as a manuscript by Popovici and colleagues entitled "Identification of a poor prognosis BRAF-mutant-like population of colon cancer patients". In this manuscript, a molecular signature that characterizes a subgroup of colorectal cancers that behave like BRAF mutant tumors but do not have true BRAF mutations. The research moves beyond analysis of a single gene to characterize a tumor’s phenotype.